Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01624467 · ClinicalTrials.gov registry record · Phase 2
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT01624467 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 75 participants.
The verdict
NCT01624467, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with necitumumab monotherapy affects the QT/QTc interval among participants with advanced solid tumors refractory to standard treatment or for which no standard treatment is available.
Interventions
- BIOLOGICAL Necitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01624467
The ClinicalTrials.gov registry entry for NCT01624467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Necitumumab is the first listed.
NCT01624467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01624467 about?
NCT01624467 is a clinical study titled "A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors". The purpose of this study is to determine whether treatment with necitumumab monotherapy affects the QT/QTc interval among participants with advanced solid tumors refractory to standard treatment or for which no standard treatment is available.
What is the current status of trial NCT01624467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2012-08. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01624467?
The interventions under investigation include: Necitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01624467?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.